Share Price and Basic Stock Data
Last Updated: November 2, 2025, 3:07 am
| PEG Ratio | -1.25 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Vaxtex Cotfab Ltd operates in the textile industry, with a market capitalization of ₹17.8 Cr. The company reported a share price of ₹0.97 and a price-to-earnings (P/E) ratio of 17.3. Revenue from operations has shown significant fluctuations over recent years. In FY 2023, the company reported sales of ₹75.62 Cr, a notable rise from ₹61.91 Cr in FY 2022. However, projections for FY 2024 indicate a sharp decline, with revenues expected to stand at ₹16.62 Cr, followed by further reduction to ₹5.25 Cr in FY 2025. This revenue volatility raises concerns about the sustainability of operations, particularly as quarterly sales have plummeted to just ₹4.10 Cr in September 2023, and a negative figure of -₹0.40 Cr is projected for March 2024. The company’s operational challenges and declining sales trajectory warrant scrutiny as they may impact future growth prospects.
Profitability and Efficiency Metrics
Vaxtex Cotfab Ltd’s profitability metrics reveal a concerning state, with a reported net profit of ₹1.03 Cr in FY 2025, down from ₹1.13 Cr in FY 2023. The operating profit margin (OPM) has fluctuated significantly, standing at 11.96% in FY 2025, but has been negative in recent quarters, indicating operational inefficiencies. The return on equity (ROE) of 4.74% and return on capital employed (ROCE) of 1.77% reflect low capital efficiency compared to industry standards. The company’s interest coverage ratio (ICR) of 5.58x suggests it can cover its interest obligations comfortably. However, the cash conversion cycle (CCC) has reached an alarming 971.94 days, indicating severe inefficiencies in managing accounts receivable and inventory, which could lead to cash flow issues. Such inefficiencies must be addressed to improve overall profitability and operational health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vaxtex Cotfab Ltd shows a total debt of ₹11.13 Cr, which presents a debt-to-equity ratio of 0.60x, reflecting a moderate level of leverage. The company’s reserves have turned negative at ₹-0.04 Cr, indicating potential financial distress. The current ratio stands at 1.80, which is above the industry norm, suggesting adequate short-term liquidity. However, the book value per share has declined to ₹0.99 from ₹1.86 in FY 2023, reflecting diminished asset value and investor confidence. The company’s price-to-book value (P/BV) ratio of 0.65x indicates that the stock is trading below its book value, which could present a buying opportunity if the company can restore profitability. Nevertheless, the declining operational metrics necessitate a thorough evaluation of the balance sheet to assess long-term viability.
Shareholding Pattern and Investor Confidence
Vaxtex Cotfab Ltd’s shareholding pattern reveals a significant shift in investor confidence. Promoter holdings stood at 16.47% as of June 2025, down from 36.28% in December 2022, indicating a reduction in management’s stake and potential loss of confidence in the company’s future. Conversely, public holdings have increased to 83.53%, pointing towards a shift in ownership dynamics, with retail investors taking a larger share. Foreign institutional investors (FIIs) remain absent, holding 0.00%, which may signal a lack of interest from institutional investors. The number of shareholders has increased to 41,499, suggesting growing retail interest despite the underlying financial challenges. This shift in shareholding could impact the company’s strategic direction and operational decisions moving forward.
Outlook, Risks, and Final Insight
The outlook for Vaxtex Cotfab Ltd presents both opportunities and significant risks. The company’s ability to recover from declining revenues and profitability hinges on addressing operational inefficiencies and stabilizing cash flows. Key strengths include a manageable interest coverage ratio and a high current ratio, indicating liquidity adequacy. However, risks are pronounced, with a concerning cash conversion cycle and negative reserves potentially threatening financial stability. Additionally, the declining promoter shareholding may affect investor sentiment and management’s commitment to driving growth. Should the company effectively implement strategic changes to improve operational efficiency and restore profitability, it could regain investor confidence and enhance its market position. Conversely, failure to address these challenges could lead to further financial deterioration and loss of market relevance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Vaxtex Cotfab Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 125 Cr. | 32.1 | 869/31.8 | 1.22 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,533 Cr. | 187 | 227/124 | 101 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 55.2 Cr. | 4.33 | 8.90/3.97 | 5.12 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,853.48 Cr | 262.95 | 344.63 | 101.24 | 0.22% | 11.73% | 22.92% | 9.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.33 | 18.33 | 11.39 | 16.57 | 10.84 | 4.10 | 2.08 | -0.40 | 0.00 | 0.00 | 0.00 | 5.25 | 0.00 |
| Expenses | 28.86 | 17.91 | 12.82 | 16.43 | 10.30 | 3.93 | 10.72 | 0.82 | -0.09 | 0.11 | 0.37 | 5.34 | 0.21 |
| Operating Profit | 0.47 | 0.42 | -1.43 | 0.14 | 0.54 | 0.17 | -8.64 | -1.22 | 0.09 | -0.11 | -0.37 | -0.09 | -0.21 |
| OPM % | 1.60% | 2.29% | -12.55% | 0.84% | 4.98% | 4.15% | -415.38% | -1.71% | |||||
| Other Income | 0.64 | 0.11 | 1.57 | 0.16 | 0.05 | 0.01 | 0.02 | 0.44 | 0.02 | 0.03 | 0.01 | 1.06 | 0.46 |
| Interest | 0.28 | 0.36 | -0.02 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.06 | 0.02 |
| Depreciation | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.00 | 0.00 | 0.01 | 0.01 | 0.06 | 0.01 | 0.01 |
| Profit before tax | 0.76 | 0.10 | 0.09 | 0.23 | 0.50 | 0.09 | -8.63 | -0.79 | 0.08 | -0.11 | -0.44 | 0.90 | 0.22 |
| Tax % | 0.00% | 0.00% | 0.00% | 13.04% | 26.00% | 22.22% | 0.00% | -18.99% | 0.00% | 0.00% | -11.36% | -47.78% | 0.00% |
| Net Profit | 0.77 | 0.10 | 0.09 | 0.21 | 0.37 | 0.07 | -8.63 | -0.65 | 0.08 | -0.12 | -0.39 | 1.32 | 0.22 |
| EPS in Rs | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | -0.47 | -0.04 | 0.00 | -0.01 | -0.02 | 0.07 | 0.01 |
Last Updated: August 20, 2025, 1:30 am
Below is a detailed analysis of the quarterly data for Vaxtex Cotfab Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.25 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 5.25 Cr..
- For Expenses, as of Jun 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.34 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 5.13 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Mar 2025) to -0.21 Cr., marking a decrease of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -1.71% (Mar 2025) to 0.00%, marking an increase of 1.71%.
- For Other Income, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.60 Cr..
- For Interest, as of Jun 2025, the value is 0.02 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.22 Cr.. The value appears to be declining and may need further review. It has decreased from 0.90 Cr. (Mar 2025) to 0.22 Cr., marking a decrease of 0.68 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -47.78% (Mar 2025) to 0.00%, marking an increase of 47.78%.
- For Net Profit, as of Jun 2025, the value is 0.22 Cr.. The value appears to be declining and may need further review. It has decreased from 1.32 Cr. (Mar 2025) to 0.22 Cr., marking a decrease of 1.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.07 (Mar 2025) to 0.01, marking a decrease of 0.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.63 | 4.43 | 18.45 | 21.97 | 27.76 | 26.15 | 61.91 | 75.62 | 16.62 | 5.25 | 5.25 |
| Expenses | 0.00 | 0.01 | 0.65 | 4.41 | 18.08 | 21.03 | 26.39 | 24.71 | 58.90 | 75.77 | 23.02 | 5.75 | 6.03 |
| Operating Profit | 0.00 | -0.01 | -0.02 | 0.02 | 0.37 | 0.94 | 1.37 | 1.44 | 3.01 | -0.15 | -6.40 | -0.50 | -0.78 |
| OPM % | -3.17% | 0.45% | 2.01% | 4.28% | 4.94% | 5.51% | 4.86% | -0.20% | -38.51% | -9.52% | -14.86% | ||
| Other Income | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | 0.05 | 0.02 | 0.06 | 0.38 | 2.22 | -2.21 | 1.13 | 1.56 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 1.06 | 1.09 | 1.08 | 0.63 | 0.07 | 0.11 | 0.12 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.11 | 0.14 | 0.15 | 0.30 | 0.28 | 0.15 | 0.10 | 0.09 |
| Profit before tax | 0.00 | 0.00 | 0.01 | 0.04 | 0.27 | 0.87 | 0.19 | 0.26 | 2.01 | 1.16 | -8.83 | 0.42 | 0.57 |
| Tax % | 0.00% | 50.00% | 37.04% | 31.03% | 52.63% | 30.77% | 26.37% | 2.59% | 0.00% | -111.90% | |||
| Net Profit | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 0.60 | 0.09 | 0.18 | 1.49 | 1.13 | -8.83 | 0.88 | 1.03 |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 0.60 | 0.01 | 0.01 | 0.10 | 0.06 | -0.48 | 0.05 | 0.05 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 750.00% | 252.94% | -85.00% | 100.00% | 727.78% | -24.16% | -881.42% | 109.97% |
| Change in YoY Net Profit Growth (%) | 0.00% | 650.00% | -497.06% | -337.94% | 185.00% | 627.78% | -751.94% | -857.25% | 991.38% |
Vaxtex Cotfab Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -28% |
| 3 Years: | -56% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | -16% |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -17% |
| 3 Years: | -53% |
| 1 Year: | 49% |
| Return on Equity | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -5% |
| 3 Years: | -10% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: September 10, 2025, 2:47 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 6.02 | 6.02 | 10.04 | 12.63 | 18.38 | 18.38 |
| Reserves | 3.53 | 3.53 | 3.53 | 3.55 | 3.72 | 4.33 | 2.63 | 2.85 | 0.32 | 10.85 | 0.42 | -0.04 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 3.29 | 12.62 | 10.30 | 7.45 | 5.20 | 11.51 | 11.13 |
| Other Liabilities | 0.03 | 0.00 | 0.27 | 0.75 | 5.82 | 5.49 | 6.65 | 2.52 | 6.18 | 40.80 | 18.56 | 19.00 |
| Total Liabilities | 3.96 | 3.93 | 4.20 | 4.70 | 10.19 | 13.51 | 27.92 | 21.69 | 23.99 | 69.48 | 48.87 | 48.47 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.36 | 1.70 | 1.80 | 2.37 | 3.85 | 3.90 | 3.65 | 1.14 | 1.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.89 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.08 | 1.05 | 1.10 | 7.01 | 7.54 |
| Other Assets | 3.07 | 3.88 | 4.20 | 4.34 | 8.49 | 11.71 | 25.43 | 17.76 | 19.04 | 64.73 | 40.72 | 39.89 |
| Total Assets | 3.96 | 3.93 | 4.20 | 4.70 | 10.19 | 13.51 | 27.92 | 21.69 | 23.99 | 69.48 | 48.87 | 48.47 |
Below is a detailed analysis of the balance sheet data for Vaxtex Cotfab Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 18.38 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 18.38 Cr..
- For Reserves, as of Mar 2025, the value is -0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.42 Cr. (Mar 2024) to -0.04 Cr., marking a decrease of 0.46 Cr..
- For Borrowings, as of Mar 2025, the value is 11.13 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 11.51 Cr. (Mar 2024) to 11.13 Cr., marking a decrease of 0.38 Cr..
- For Other Liabilities, as of Mar 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.56 Cr. (Mar 2024) to 19.00 Cr., marking an increase of 0.44 Cr..
- For Total Liabilities, as of Mar 2025, the value is 48.47 Cr.. The value appears to be improving (decreasing). It has decreased from 48.87 Cr. (Mar 2024) to 48.47 Cr., marking a decrease of 0.40 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.14 Cr. (Mar 2024) to 1.04 Cr., marking a decrease of 0.10 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 7.54 Cr.. The value appears strong and on an upward trend. It has increased from 7.01 Cr. (Mar 2024) to 7.54 Cr., marking an increase of 0.53 Cr..
- For Other Assets, as of Mar 2025, the value is 39.89 Cr.. The value appears to be declining and may need further review. It has decreased from 40.72 Cr. (Mar 2024) to 39.89 Cr., marking a decrease of 0.83 Cr..
- For Total Assets, as of Mar 2025, the value is 48.47 Cr.. The value appears to be declining and may need further review. It has decreased from 48.87 Cr. (Mar 2024) to 48.47 Cr., marking a decrease of 0.40 Cr..
However, the Borrowings (11.13 Cr.) are higher than the Reserves (-0.04 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -0.01 | -0.02 | 0.02 | 0.12 | -2.35 | -11.25 | -8.86 | -4.44 | -5.35 | -17.91 | -11.63 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 121.67 | 139.24 | 60.93 | 78.08 | 112.42 | 136.65 | 36.49 | 87.94 | 345.02 | 971.94 | ||
| Inventory Days | 64.04 | 35.35 | 35.24 | 15.72 | 70.56 | 28.50 | 36.53 | 6.96 | 3.50 | 0.00 | ||
| Days Payable | 160.09 | 53.91 | 133.87 | 127.24 | 104.80 | 36.50 | 35.52 | 152.60 | 293.74 | |||
| Cash Conversion Cycle | 25.61 | 120.68 | -37.69 | -33.44 | 78.17 | 128.65 | 37.51 | -57.70 | 54.78 | 971.94 | ||
| Working Capital Days | 28.97 | 290.02 | 45.30 | 15.78 | 88.09 | 211.04 | 68.04 | 116.08 | 458.56 | 1,177.04 | ||
| ROCE % | 0.00% | 0.00% | 0.25% | 1.02% | 6.49% | 14.21% | 8.54% | 6.68% | 16.71% | 2.02% | -20.72% | 1.77% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 2.00 | 10.00 |
| Basic EPS (Rs.) | 0.05 | -0.59 | 0.11 | 0.30 | 0.30 |
| Diluted EPS (Rs.) | 0.05 | -0.59 | 0.11 | 0.30 | 0.30 |
| Cash EPS (Rs.) | 0.05 | -0.47 | 0.11 | 0.35 | 0.54 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.99 | 1.02 | 1.86 | 2.06 | 14.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.99 | 1.02 | 1.86 | 2.06 | 14.73 |
| Revenue From Operations / Share (Rs.) | 0.28 | 0.90 | 5.99 | 12.33 | 43.42 |
| PBDIT / Share (Rs.) | 0.03 | -0.46 | 0.04 | 0.67 | 2.49 |
| PBIT / Share (Rs.) | 0.02 | -0.47 | 0.01 | 0.61 | 2.24 |
| PBT / Share (Rs.) | 0.02 | -0.48 | 0.09 | 0.40 | 0.43 |
| Net Profit / Share (Rs.) | 0.04 | -0.48 | 0.08 | 0.29 | 0.29 |
| PBDIT Margin (%) | 11.96 | -51.83 | 0.67 | 5.46 | 5.72 |
| PBIT Margin (%) | 9.97 | -52.75 | 0.30 | 4.98 | 5.15 |
| PBT Margin (%) | 7.83 | -53.15 | 1.53 | 3.24 | 1.00 |
| Net Profit Margin (%) | 16.81 | -53.15 | 1.49 | 2.39 | 0.68 |
| Return on Networth / Equity (%) | 4.81 | -47.01 | 4.82 | 14.34 | 2.00 |
| Return on Capital Employeed (%) | 2.03 | -30.18 | 0.80 | 18.53 | 7.04 |
| Return On Assets (%) | 1.82 | -18.07 | 1.62 | 6.19 | 0.82 |
| Long Term Debt / Equity (X) | 0.40 | 0.53 | 0.22 | 0.58 | 1.14 |
| Total Debt / Equity (X) | 0.60 | 0.61 | 0.22 | 0.71 | 1.16 |
| Asset Turnover Ratio (%) | 0.10 | 0.28 | 1.62 | 2.71 | 1.05 |
| Current Ratio (X) | 1.80 | 2.11 | 1.62 | 2.72 | 5.11 |
| Quick Ratio (X) | 1.80 | 2.10 | 1.59 | 1.99 | 4.44 |
| Inventory Turnover Ratio (X) | 48.96 | 21.35 | 19.63 | 16.24 | 7.54 |
| Interest Coverage Ratio (X) | 5.58 | -130.94 | 0.81 | 3.15 | 1.38 |
| Interest Coverage Ratio (Post Tax) (X) | 8.85 | -133.26 | 0.32 | 2.38 | 1.16 |
| Enterprise Value (Cr.) | 23.07 | 28.95 | 32.88 | 125.26 | 36.65 |
| EV / Net Operating Revenue (X) | 4.39 | 1.74 | 0.43 | 2.02 | 1.40 |
| EV / EBITDA (X) | 36.72 | -3.36 | 64.30 | 37.03 | 24.46 |
| MarketCap / Net Operating Revenue (X) | 2.27 | 1.05 | 0.36 | 1.91 | 1.01 |
| Price / BV (X) | 0.65 | 0.92 | 1.18 | 11.39 | 2.98 |
| Price / Net Operating Revenue (X) | 2.27 | 1.05 | 0.36 | 1.91 | 1.01 |
| EarningsYield | 0.07 | -0.50 | 0.04 | 0.01 | 0.01 |
After reviewing the key financial ratios for Vaxtex Cotfab Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.59 (Mar 24) to 0.05, marking an increase of 0.64.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.59 (Mar 24) to 0.05, marking an increase of 0.64.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has increased from -0.47 (Mar 24) to 0.05, marking an increase of 0.52.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.99. It has decreased from 1.02 (Mar 24) to 0.99, marking a decrease of 0.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.99. It has decreased from 1.02 (Mar 24) to 0.99, marking a decrease of 0.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.28. It has decreased from 0.90 (Mar 24) to 0.28, marking a decrease of 0.62.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has increased from -0.46 (Mar 24) to 0.03, marking an increase of 0.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from -0.47 (Mar 24) to 0.02, marking an increase of 0.49.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from -0.48 (Mar 24) to 0.02, marking an increase of 0.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 2. It has increased from -0.48 (Mar 24) to 0.04, marking an increase of 0.52.
- For PBDIT Margin (%), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from -51.83 (Mar 24) to 11.96, marking an increase of 63.79.
- For PBIT Margin (%), as of Mar 25, the value is 9.97. This value is below the healthy minimum of 10. It has increased from -52.75 (Mar 24) to 9.97, marking an increase of 62.72.
- For PBT Margin (%), as of Mar 25, the value is 7.83. This value is below the healthy minimum of 10. It has increased from -53.15 (Mar 24) to 7.83, marking an increase of 60.98.
- For Net Profit Margin (%), as of Mar 25, the value is 16.81. This value exceeds the healthy maximum of 10. It has increased from -53.15 (Mar 24) to 16.81, marking an increase of 69.96.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has increased from -47.01 (Mar 24) to 4.81, marking an increase of 51.82.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.03. This value is below the healthy minimum of 10. It has increased from -30.18 (Mar 24) to 2.03, marking an increase of 32.21.
- For Return On Assets (%), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 5. It has increased from -18.07 (Mar 24) to 1.82, marking an increase of 19.89.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.53 (Mar 24) to 0.40, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.61 (Mar 24) to 0.60, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.28 (Mar 24) to 0.10, marking a decrease of 0.18.
- For Current Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 2.11 (Mar 24) to 1.80, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.80, marking a decrease of 0.30.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 48.96. This value exceeds the healthy maximum of 8. It has increased from 21.35 (Mar 24) to 48.96, marking an increase of 27.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.58. This value is within the healthy range. It has increased from -130.94 (Mar 24) to 5.58, marking an increase of 136.52.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has increased from -133.26 (Mar 24) to 8.85, marking an increase of 142.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23.07. It has decreased from 28.95 (Mar 24) to 23.07, marking a decrease of 5.88.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.39. This value exceeds the healthy maximum of 3. It has increased from 1.74 (Mar 24) to 4.39, marking an increase of 2.65.
- For EV / EBITDA (X), as of Mar 25, the value is 36.72. This value exceeds the healthy maximum of 15. It has increased from -3.36 (Mar 24) to 36.72, marking an increase of 40.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 2.27, marking an increase of 1.22.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.65, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 2.27, marking an increase of 1.22.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from -0.50 (Mar 24) to 0.07, marking an increase of 0.57.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaxtex Cotfab Ltd:
- Net Profit Margin: 16.81%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.03% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.8
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.2 (Industry average Stock P/E: 344.63)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.81%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Textiles - General | J-03 (GF to 4th Floor) Tejendra Arcade, Nr, Ganjifarak Mill Compound, Ahmedabad Gujarat 380023 | vaxtexcotfab@gmail.com www.vaxtexcotfabltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aakash Rajeshbhai Thakor | Managing Director |
| Mr. Devi Singh | Non Executive Director |
| Mr. Pranav Vajani | Independent Director |
| Mr. Ravi Jitendra Modi | Independent Director |
| Mr. Harsh Mahendrakumar Kothari | Independent Director |
| Ms. Hardika Ladha | Independent Director |
FAQ
What is the intrinsic value of Vaxtex Cotfab Ltd?
Vaxtex Cotfab Ltd's intrinsic value (as of 04 November 2025) is 0.63 which is 30.77% lower the current market price of 0.91, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 16.7 Cr. market cap, FY2025-2026 high/low of 1.31/0.60, reserves of ₹-0.04 Cr, and liabilities of 48.47 Cr.
What is the Market Cap of Vaxtex Cotfab Ltd?
The Market Cap of Vaxtex Cotfab Ltd is 16.7 Cr..
What is the current Stock Price of Vaxtex Cotfab Ltd as on 04 November 2025?
The current stock price of Vaxtex Cotfab Ltd as on 04 November 2025 is 0.91.
What is the High / Low of Vaxtex Cotfab Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaxtex Cotfab Ltd stocks is 1.31/0.60.
What is the Stock P/E of Vaxtex Cotfab Ltd?
The Stock P/E of Vaxtex Cotfab Ltd is 16.2.
What is the Book Value of Vaxtex Cotfab Ltd?
The Book Value of Vaxtex Cotfab Ltd is 1.00.
What is the Dividend Yield of Vaxtex Cotfab Ltd?
The Dividend Yield of Vaxtex Cotfab Ltd is 0.00 %.
What is the ROCE of Vaxtex Cotfab Ltd?
The ROCE of Vaxtex Cotfab Ltd is 1.77 %.
What is the ROE of Vaxtex Cotfab Ltd?
The ROE of Vaxtex Cotfab Ltd is 4.74 %.
What is the Face Value of Vaxtex Cotfab Ltd?
The Face Value of Vaxtex Cotfab Ltd is 1.00.